Cancer Trials Need New Endpoints For Progression, FDA Guidance Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cancer trials need new methods of measuring progression, FDA guidance says. Draft document on clinical trial endpoints for cancer drugs advocates survival as “gold standard,” but discusses value of progression assessment as potential surrogate marker
You may also be interested in...
Bayer/Onyx Nexavar FDA Review Shows Debate Over Full Vs. Subpart H Approval
Review documents for Bayer/Onyx’ Nexavar show disagreement within FDA regarding whether to grant the advanced renal cell carcinoma agent full or accelerated approval.
Talabostat SPA "Unnecessary" Given Available Cancer Guidance – Point
A special protocol assessment was "unnecessary" for Phase III trials of Point Therapeutics’ oncologic talabostat given the availability of "clear guidance" on cancer trial endpoints from FDA, Chief Development Officer Margaret Uprichard told a clinical update teleconference Jan. 31.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011